Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly expresses EBNA3A with conserved CD8+ T-cell epitopes by Nguyen-Van, Do et al.
This is the author’s version of a work that was submitted/accepted for pub-
lication in the following source:
Nguyen-Van, Do, Keane, Colm, Han, Erica, Jones, Kimberley, Nourse,
Jamie P., Vari, Frank, Ross, Nathan, Crooks, Pauline, Ramuz, Olivier,
Green, Michael, Griffiths, Lyn R., Trappe, Ralf, Grigg, Andrew, Mollee,
Peter, & Gandhi, Maher K. (2011) Epstein-Barr virus-positive diffuse large
B-cell lymphoma of the elderly expresses EBNA3A with conserved CD8+
T-cell epitopes. American Journal of Blood Research, 1(2), pp. 146-159.
This file was downloaded from: http://eprints.qut.edu.au/63626/
c© Copyright 2011 E-Century Publishing Corporation
Notice: Changes introduced as a result of publishing processes such as
copy-editing and formatting may not be reflected in this document. For a
definitive version of this work, please refer to the published source:
  
Introduction 
 
Immunosuppression is the most frequently rec-
ognized predisposing factor to lymphoma. The 
importance of defective immunosurveillance in 
malignancy is most marked in cells with strong 
antigenic potential including those that have 
undergone viral induction. Consistent with this 
observation, is the archetypal immunosuppres-
sion associated lymphoma: post-transplantation 
lymphoproliferative disorder (PTLD). Relative to 
the immunocompetent patient, the risk of lym-
phoma after transplantation is increased by the 
order of 30-times [1, 2]. PTLD is frequently as-
sociated with Epstein-Barr virus (EBV) positivity 
within the malignant B-cells. PTLD is sub-divided 
into poly and monomorphic histological sub-
types. It is believed to have a latency gene ex-
pression program (latency III) analogous to in-
vitro EBV-transformed lymphoblastoid cell-lines 
(LCL), in which all EBV-latent antigens are ex-
pressed including the immuno-dominant EB-
NA3A [3].  
 
The most frequent histological sub-type of PTLD 
is diffuse large B-cell lymphoma (EBV+DLBCL-
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Abstract: Post-transplantation lymphoproliferative disorders (PTLD) arise in the immunosuppressed and are fre-
quently Epstein-Barr virus (EBV) associated. The most common PTLD histological sub-type is diffuse large B-cell lym-
phoma (EBV+DLBCL-PTLD). Restoration of EBV-specific T-cell immunity can induce EBV+DLBCL-PTLD regression. The 
most frequent B-cell lymphoma in the immunocompetent is also DLBCL. ‘EBV-positive DLBCL of the eld-
erly’ (EBV+DLBCL) is a rare but well-recognized DLBCL entity that occurs in the overtly immunocompetent, that has 
an adverse outcome relative to EBV-negative DLBCL. Unlike PTLD (which is classified as viral latency III), literature 
suggests EBV+DLBCL is typically latency II, i.e. expression is limited to the immuno-subdominant EBNA1, LMP1 and 
LMP2 EBV-proteins. If correct, this would be a major impediment for T-cell immunotherapeutic strategies. Unexpect-
edly we observed EBV+DLBCL-PTLD and EBV+DLBCL both shared features consistent with type III EBV-latency, includ-
ing expression of the immuno-dominant EBNA3A protein. Extensive analysis showed frequent polymorphisms in EB-
NA1 and LMP1 functionally defined CD8+ T-cell epitope encoding regions, whereas EBNA3A polymorphisms were very 
rare making this an attractive immunotherapy target. As with EBV+DLBCL-PTLD, the antigen presenting machinery 
within lymphomatous nodes was intact. EBV+DLBCL express EBNA3A suggesting it is amenable to immunotherapeu-
tic strategies. 
 
Keywords: Epstein-Barr virus, diffuse large B-cell lymphoma, EBNA3A, T-cell, epitope, immunotherapy, post-
transplantation lymphoproliferative disorder 
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PTLD). Similarly, the most frequent B-cell lym-
phoma histology in the immunocompetent is 
DLBCL, representing 30% of all non-Hodgkin 
lymphoma. DLBCL is a biologically and clinically 
heterogeneous aggressive lymphoma. The 
World Health Organization (WHO) recently clas-
sified a provisional new sub-type of DLBCL aris-
ing in immunocompetent patients that is EBV-
associated, termed ‘EBV-positive DLBCL of the 
elderly’ (EBV+DLBCL) [4, 5]. It is defined as oc-
curring in those over 50 years of age without a 
predisposing immune deficiency [4]. Cases are 
consistently c-myc rearrangement negative [6]. 
In Korea, Turkey, Spain and Japan the rates of 
EBV+DLBCL are approximately 5-10% [7-10]. 
The proportion rises with age (~30% in the >90 
years) [8]. With the numbers of elderly predicted 
to markedly rise in many developed countries, 
EBV+DLBCL is likely to be an increasing health 
burden. EBV-encoded RNA in situ hybridization 
(EBER-ISH) on diagnostic DLBCL biopsies is not 
routine in many centres and data on frequency 
is limited and conflicting [9, 11, 12]. However a 
consistent finding from large series is that 
EBV+DLBCL is associated with reduced re-
sponse to front-line chemotherapy therapy and 
reduced survival relative to EBV-negative DLBCL 
[7]. PTLD arises in patients given iatrogenic im-
munosuppression to prevent rejection of their 
transplanted organ. Antigen presentation in 
PTLD remains intact and defective immuno-
surveillance is strongly implicated in pathogene-
sis [2]. Furthermore restoration of EBV-specific 
T-cell immunity by cellular immunotherapy can 
result in long-term regression [13]. The WHO 
postulate that EBV+DLBCL is related to deterio-
ration in immunity as part of the ageing process 
[4]. If correct, this would also implicate defec-
tive immuno-surveillance and suggests that 
EBV+DLBCL could potentially be treated by 
novel immune-based strategies including adop-
tive immunotherapy. There is a well-defined 
hierarchy of EBV-specific T-cell immunity against 
EBV-latent antigens in which EBV-nuclear anti-
gen (EBNA)-1 and Latent Membrane Proteins 
(LMP)-1 and 2 elicit sub-dominant responses 
relative to EBNA2/3A/3B and 3C. Furthermore, 
variations in functionally defined EBV T-cell epi-
topes will influence whether EBV-specific T-cells 
generated by immunotherapy can recognize the 
viral strains expressed in the lymphoma. There-
fore the prerequisite data necessary before 
such approaches can be considered includes 
EBV+DLBCL’s viral protein expression, the lym-
phomas antigen presentation capability and the 
polymorphisms present within antigenic deter-
minants. This study aims to demonstrate 
whether this new and highly aggressive lym-
phoma entity has characteristics amenable to T-
cell based immunotherapies.  
  
Materials and methods 
 
Patient samples 
 
All patients with EBV+DLBCL were aged over 50 
years (mean 67 years, range 59-90). For 
EBV+DLBCL-PTLD, average age was 39 years 
(range 17-58). Patients were chosen solely on 
the availability of tissue. The majority of tissues 
were formalin-fixed paraffin-embedded (FFPE). 
DLBCL and EBV+DLBCL-PTLD samples were 
obtained from the Princess Alexandra Hospital, 
Brisbane, the Austin Hospital, Melbourne and 
the Department of Hematology and Oncology, 
Campus Virchow-Klinikum, Charité Universitäts-
medizin Berlin. Three frozen tissues (two 
EBV+DLBCL and one EBV+DLBCL-PTLD) were 
supplied by the Australasian Leukaemia Lym-
phoma Group Tissue Bank. Cases were evalu-
ated by a lymphoma pathologist (O.M.) as posi-
tive for EBV-encoded-RNA in-situ-hybridization 
(EBER-ISH) with a positive EBER-ISH reaction 
defined as ≥20% of nuclei positivity of examined 
cells [7]. EBV-tissue positivity was in all cases 
confirmed by real-time PCR for EBER-DNA (Table 
1A). All patients were Human Immunodeficiency 
Virus (HIV) negative and (for EBV+DLBCL) not on 
immunosuppression medication. Transformed 
lymphoma and follicular lymphoma grade 3B 
were excluded. The study was approved by the 
relevant Human Research Ethics Committees 
and conducted in accordance with the Declara-
tion of Helsinki. The patients reflected the eth-
nicity of the respective Hospital catchment ar-
eas. One was of Pacific Islander extraction 
(DL67); the others were Caucasian.  
 
Cell-lines 
 
The following were used: Burkitt’s lymphoma 
(BL) cell-lines without EBV: BJAB and Ramos; 
lymphoblastoid cell-line (LCL) DeMo (EBV+ B95-
8); and T2 (transporter-associated protein [TAP1 
and TAP2] deficient lymphoid cells).  
 
In situ hybridization and immunohistochemistry  
 
EBER -1 and -2 oligonucleotide probes (Leica 
Microsystems, UK) for EBER-ISH and immuno-
histochemistry for LMP1 (Dako, Germany), were 
performed as previously described [14]. EB-
EBV+DLBCL expresses EBNA3A  
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NA3A (ab16126, Abcam, UK) was used at a 
dilution of 1/1000, with a ready-to-use Goat 
Horse Radish Peroxidase secondary antibody. 
Human Leucocyte Antigen (HLA) class I, TAP1 
and TAP2 (Abcam, UK ab70328, ab60112, 
ab60113 respectively) were performed as per 
manufacturer’s instructions.  
 
Nucleic acid extraction  
 
RecoverAll Total Nucleic Acid Isolation Kit 
(Applied Biosystems, TX, USA) were employed 
for simultaneous DNA and total RNA extractions 
from FFPE tissue sections as manufacturer’s 
instructions. For cell-lines and frozen tissues, 
DNA and RNA was extracted by QIAamp DNA 
blood mini-kit (QIAGEN, Hilden, Germany) and 
mirVana RNA isolation kit (Applied Biosystems, 
TX, USA) respectively as manufacturer’s instruc-
tions. To remove contaminated DNA in total 
RNA, the TURBO DNA-free Kit (Applied Biosys-
tems, USA) was used for all RNA samples. Both 
Table 1. Oligonucleotide primers and probes 
1A. Oligonucleotide primer/probe combinations for EBV gDNA real-time PCR 
Gene Primer name Sequence 5’-3’ 
Co-ordinate 
(AJ507799.2) 
Alb* Alb-F1 GCTGTCATCTCTTGTGGGCTGT 19583-19604 
  Alb-R1 AAACTCATGGGAGCTGCTGGTT 19723-19702 
  Probe CCTGTCATGCCCACACAAATCTCTCC 19640-19665 
EBER EBER-F1 AAACCTCAGGACCTACGCTGC 6622-6642 
  EBER-R1 AGACACCGTCCTCACCAC 6726-6709 
  Probe TAGAGGTTTTGCTAGGGAGGAGACGTG 6645-6671 
*Genbank accession number: NG_009291.1 
  
1B. Oligonucleotide primers for EBV gene expression profile and HLA class I, TAP1, TAP2 expressions by 
real-time RT-PCR 
    
Transcript Primer 
name 
Sequence 5’-3’ Co-ordinate 
(AJ507799.2) 
EBNA2 Y2/YH-T1F1 GCTTAGCCAGTAACCCAGCACT 35702-35711/36098-
36109 
  YH-R2 TGCTTAGAAGGTTGTTGGCATG 36181-36160 
EBNA3A BLRF3/BERF1-F1 GGCTACGCGCATCGACACA 80287-80293/80382-
80393 
  BERF1-R2 TGTACATCTCGGTATTTGAAATCTGGG 80445-80419 
LMP1 LMP1-F2 TTGTATACTCCTACTGATGATCACCCTCC 168768-168749/168670-
168678 
  LMP1-R2 ACAATGCCTGTCCGTGCAAATTCC 168623-168646 
LMP2A LMP2A-F1 ATACGAAGAAGCGGGCAGAGG 166435-166455 
  LMP2A/B-R1 GAGGTAGGGCGCAACAATTACAGG 100-77 
LMP2B LMP2B-F1 GGGAGGCCGTGCTTTAGGGG 169422-169441 
  LMP2A/B-R1 GAGGTAGGGCGCAACAATTACAGG 100-77 
BART BART-F1 AGATGCCCTCCAGGTCAAAGA 156884-156904 
  BART-R1 ATCCAGTGTCCCTCGTTTGG 158669-158650 
HLA class I* HLA-A-F1 AGGAGGAAGAGCTCAGATAGAAAA 997-1020 
  HLA-A-R1 AAGCTGTGAGGGACACATCA 1087-1068 
TAP1** TAP1-F1 TCTCACCATAGCCAGTGCAG 1034-1053 
  TAP1-R1 GTGGCCCATGGTGTTGTTAT 1100-1080 
TAP2*** TAP2-F1 TTCTCCTTTGGCAGCTCACT 717-736 
  TAP2-R1 ATCCGCAAGTTGATTCGAGA 796-777 
B2M**** B2M-F1 TCACCCCCACTGAAAAAGATG 329-349 
  B2M-R1 ATGATGCTGCTTACATGTCTCG 430-409 
GenBank accesion number: *NM_002116.5,**NM_000593.5,***NM_000544.3,****NM_004048.2 
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the quality and quantity of purified DNA and 
RNA were measured by a NanoDrop ND-100 
spectrophotometer (Wilmington, DE, USA). All 
genomic DNA and total RNA were store at -200C 
and -800C, respectively.  
 
Real-time comparative quantification PCR 
 
Primers to identify EBV gene / expression 
(Sigma Aldrich, Victoria, Australia) were de-
signed for PCR / real-time reverse-transcription 
(RT) PCR respectively, as shown in Table 1B. 
Primers were designed to pick up the tran-
scripts in a spliced adjunction to eliminate the 
amplification of DNA remaining in the total RNA. 
Product sizes were between 60-100bp to en-
sure suitability for the amplification of RNA ex-
tracted from FFPE sections. β2M was used as 
the internal control for each sample. The DeMo 
(B95-8 EBV) LCL is used as a calibrator for all 
studied genes. Real-time RT-PCR was performed 
in 20 µl of reaction using SYBR Green PCR Mas-
ter Mix (Applied Biosystems, UK) with 5µl diluted 
cDNA and the thermal cycle was as: 370C x 10 
minutes; 950C x 10 minutes; 40 cycles: 950C x 
15 seconds, 600C x 45 seconds running by the 
Rotor-Gene 3000. The data were analysed us-
ing Rotor-Gene 6.0 and Microsoft Excel 2007 
and the amplified products were also checked 
by the separation in 2.5% agarose gel with 
ethidium bromide staining and visualized under 
UV light. The heat-map was generated by Gene-
sis software v1.0. Primers for HLA-A, TAP1 and 
TAP2 for real-time RT-PCR are shown in Table 
1B. 
 
CD8+ T-cell epitope sequencing for EBNA1, 
LMP1 and EBNA3A and phylogenetic analysis 
 
To enable CD8+ T-cell epitope sequencing and 
phylogenetic analysis, selected DNA regions 
were chosen for PCR amplification and se-
quence analysis [15, 16]. The primers (Table 
1C) were designed using Primer3 software and 
were synthesized by Sigma-Aldrich, Victoria, 
Australia. A nested PCR was done with the same 
primers in PCR1 or using inner primers for the 
samples that were negative in the first round 
PCR. All PCR products were purified using 
QIAquick Gel Extraction Kit (QIAGEN, Germany). 
The sequence analysis was performed using the 
BigDye 3.1 sequencing protocol (Applied Biosys-
tems, USA). Briefly, the BigDye reaction was 
performed containing 1.2µl of BigDye termina-
tor v3.1, 3.6 µl of 5x sequencing buffer, 1ng 
template DNA per 100bp and 3.2 pmol primer 
in a total 12µl amplification reaction. The ther-
mal cycles included an initial denature 940C x 2 
minutes and then 35 cycles: 940C x 10 sec-
onds, 500C x 5 seconds and 600C x 2 minutes. 
DNA was precipitated with 72µl of 70% isopro-
panol at room temperature x 15 minutes and 
centrifuged at 13,000rpm x 30 minutes. The 
DNA was dried for one hour at room tempera-
1C. Oligonucleotide primers for PCR amplification and sequence analysis 
Gene Primer name Sequence 5’-3’ Co-ordinate (AJ507799.2) 
EBNA1 E1C-F1 AAAAAGGAGGGTGGTTTGGA 97040-97059 
  E1C-R1 CATTCCAAAGGGGAGACGAC 97290-97271 
LMP1 LMP1C-F4 TGACATGGTAATGCCTAGAAGTAAA 167671-167695 
  LMP1C-R3 CTGGAGGTGGTCCTGACAAT 168129-168110 
EBNA2A 
  
EBNA2A-F AACTTCAACCCACACCATCA 36925-36944 
EBNA2A-R TTCTGGACTATCTGGATCAT 37040-37021 
EBNA2B* 
  
EBNA2B-F TACTCTTCCTCAACCCAGAA 36749-36768 
EBNA2B-R GGTGGTAGACTTAGTTGATG 36868-36849 
EBNA3A E3A-F6 ATGTATGCCATGGCCATTC 92736-92754 
  E3A-R6 TCCTCCCAGATTTTCGTGAG 93127-93108 
  E3A-F7 TCGCCAGTGGTTGTATGTTC 93008-93027 
  E3A-R7 TTTCACCGGTAGCACCTTC 93378-93360 
  E3A-F3 ACGGCACAGGCTTGGAAT 93279-93296 
  E3A-R8 GTTGGGGGTTCTGGGACTT 93673-93655 
  E3A-F8 ACCAGAGGTCCCACAAAGC 93605-93623 
  E3A-R3 ACAGGGACGGGTTCTACTGG 93949-93930 
Note: *GenBank accession number: DQ279927.1. EBNA2A and EBNA2B primers are for PCR amplification of EBV 
types 1 and 2, respectively. 
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ture and diluted in 20µl formamide. The se-
quence analysis was run by ABI 3100 auto-
mated DNA sequencer (Applied Biosystems, CA, 
USA). Data was analysed with the FinchTV 1.4 
DNA sequence analysis program (http://en.bio-
soft.net/dna/FinchTV.html). The phylogenetic 
trees were drawn as previously outlined [16] 
from amino acid sequences using ClustalW2 
(www.ebi.ac.uk/Tools/clustalw2) for 
EBV+DLBCL and EBV+DLBCL-PTLD and for 
three EBV strains from GenBank: B95-8 
(V01555), AG876 (DQ279927.1) and GD1 
(AY961628.3). 
 
Results 
 
EBV+DLBCL has a latency profile similar to 
EBV+DLBCL-PTLD   
 
To further characterize the EBV latency profile, 
we performed real-time RT-PCR on a series of 
seven EBV+DLBCL and seven EBV+DLBCL-PTLD 
cases (Table 3). In agreement with prior work in 
EBV-positive cancers, expression was not identi-
cal in all samples [17-19]. There was no dis-
cernable differences between EBV+DLBCL and 
EBV+DLBCL-PTLD. In most cases the majority of 
EBV latent antigens were expressed, consistent 
with type III latency. EBNA3A was strongly ex-
pressed (defined as equivalent or above DeMo 
LCL) in 12/14 cases, whereas EBNA2 was 
strongly expressed in only 4/14, consistent with 
the low detection rate of EBNA2 by immunohis-
tochemistry by others [4, 8]. The EBNA2 region 
Table 2. Summary of EBNA1 sub-types and LMP1 variants detected in EBV+DLBCL-PTLD and 
EBV+DLBCL 
No Samp. 
    EBNA1 SUB-TYPES 
  
LMP1 VARIANTS 
 
  
P-ala P-ala-v2 P-thr 
V-val-v3 
  B95-8 Ch1 Ch2 AL NC Med- Med+ 
1 PDL3 EB
V
+
D
L
B
C
L
-
P
T
L
D 
+# - - -   + - - - - - - 
2 PDL4 - - + -   - - - - - + - 
3 PDL5 - - + -   ND 
4 PDL6 - - + -   - + - - - - - 
5 PDL7 +# - - -   + - - - - - - 
6 PDL8 - + + -   - - - - + + - 
7 PDL9 + - - 
- 
  + - - - - - - 
8 DL4 
E
B
V
+
D
L
B
C
L 
- - + -   - + - - - - - 
9 DL14 +# - - -   ND 
10 DL26 - - + -   - - - - - + - 
11 DL29 - - + -   - + - - - - - 
12 DL44 - + - -   - - - - + - - 
13 DL67 - - - +   - - + - - - - 
14 DL82 - - + -   - + - - - - - 
Note: EBNA1 and LMP1 were sub-typed as previously described.[15, 16] “+” the sub-type detected, and “-“ is unde-
tected. V-val-v3 is a sub-type of V-val (P529Q), due to two sub-types V-val-v1 and V-val-v2. ND: not done. PDL: 
EBV+DLBCL-PTLD; DL: EBV+DLBCL. #Some minor changes compared with P-ala: PDL3 and PLD7: E483D; DL14: 
E500K. 
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we amplified (to distinguish EBV types 1 and 2) 
spanned this deleted region. Since DNA from 
this region could be amplified in all cases, the 
low EBNA2 / high EBNA3A gene expression pat-
tern we observed in EBV+DLBCL was not due to 
the EBNA2 gene deletion. Protein expression 
was tested by immunohistochemistry in nine 
DLBCL cases with either high or low viral latent 
gene expression. LMP1 and EBNA3 protein was 
detectable in all cases with high gene expres-
sion, and not in those with low expression 
(Figure 1).  
 
EBV+DLBCL has similar antigen processing ma-
chinery expression to EBV+DLBCL-PTLD  
 
EBV+DLBCL-PTLD and LCL are known to be ca-
pable of presenting endogenous antigens for 
recognition by T-cells. Using immunohistochem-
istry (IHC), we compared EBV+DLBCL, 
EBV+DLBCL-PTLD and LCL for expression of the 
components of antigen processing machinery: 
MHC class I, TAP-1 and TAP-2. All were consis-
tently present, with similar results obtained on 
both frozen and paraffin-wax sections. Control 
TAP deficient cell lines were not stainable for 
TAP-1 and TAP-2. To accurately quantify and 
compare the components required for antigen 
presentation, we performed real-time RT-PCR 
for MHC class I, TAP1 and TAP2 gene expres-
sion on EBV+DLBCL, EBV+DLBCL-PTLD, and 
EBV-negative DLBCL tissues, each relative to 
the LCL line DeMo. This line was chosen as it is 
known to be capable of presenting endogenous 
EBV antigens and is regularly used as a positive 
target cell control in functional T-cell assays. 
Levels were equivalent between samples for 
each of six EBV+DLBCL, seven EBV+DLBCL-
PTLD, and seven EBV-negative DLBCL (P= NS) 
(Figure 2). 
 
Polymorphisms in EBV regions encoding for 
CD8+ T-cell epitopes are infrequent for EBNA3A 
but common for EBNA1 and LMP1 
 
There are 2 major types of EBV (types 1 and 2) 
distinguished by polymorphisms in EBNA2 [20]. 
All fourteen EBV+DLBCL and EBV+DLBCL-PTLD 
cases were type 1 (data not shown). Using di-
rect sequence analysis, the gene variations of 
Table 3. EBV gene expression profiles in EBV+DLBCL (DL4, 26, 29, 44, 67, 122, 82) and EBV+DLBCL-
PTLD (PDL3-9), using DeMo (B95-8) LCL as a calibrator for all genes. The EBV-negative lines (Ramos and 
BJAB-) and EBV-negative DLBCL-PTLD primary samples (PDL1 and PDL2) were negative controls. β2M 
expression was used as an internal control for each gene and every duplicate experiment. Assays were 
repeated in two independent experiments. 
  EBER BART LMP1 LMP2A LMP2B EBNA2 EBNA3A 
DEMO LCL + + + + + + + 
RAMO - - - - - - - 
BJAB- - - - - - - - 
PDL1 - - - - - - - 
PDL2 - - - - - - - 
PDL3 + + + + - - + 
PDL4 + + + - + + + 
PDL5 + + + + + + + 
PDL6 + + - - + - - 
PDL7 + + + + + - - 
PDL8 + + + - - - - 
PDL9 + + + - - - - 
DL4 + - - - - - + 
DL26 + + + - - - + 
DL29 + + - - + - + 
DL44 + + - - - + + 
DL67 + + - + - - + 
DL122 + + - + - - + 
DL82 + - + - - - - 
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Figure 1. EBV latent gene and protein expression. 1. Panels 1 and 2: Haematoxylin and Eosin stain, and EBER-ISH 
respectively on DL67. Panel 3: LMP1 immunohistochemistry on DL26. Panels 4-6: EBNA3A immunohistochemistry on 
an EBV-negative DLBCL, an EBV+DLBCL-PTLD (PDL6) and on DeMo LCL respectively.  
Figure 2. HLA class I, TAP1 and TAP2 gene expression in EBV+DLBCL is equivalent to EBV+DLBCL-PTLD. The expres-
sion of HLA-A, TAP1 and TAP2 was quantified by real-time RT-PCR. DeMo B95-8 LCL was used as a reference. All ex-
periments were run in duplicate and repeated once. No significant differences were observed between groups.  
EBV+DLBCL expresses EBNA3A  
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the EBNA1- and LMP1-C terminus functional 
domains were used to further type EBV into sub-
strains [16]. Consistent with previous studies of 
EBV-positive lymphomas [21, 22] in 13/14 
cases only one viral sub-strain could be identi-
fied. In polymorphic analysis of wild-type sub-
strains in biopsy samples, the EBNA1 P-ala and 
LMP1 B95-8 sub-strains type the same as the 
type 1 laboratory strain B95-8. In EBV+DLBCL 
and EBV+DLBCL-PTLD tissues respectively only 
1/7 and 3/7 samples were EBNA1 P-ala, versus 
0/6 and 3/6 with LMP1 B95-8 sub-strains 
(Table 2). By EBNA1 typing, the most frequent 
sub-type was P-thr (7/14). For LMP1, the most 
common was Ch1 (4/12). PBMC from PDL7, 
DL4 and DL82 was sequenced and the de-
tected EBNA1 and LMP1 sub-types were the 
same with that in the tumor (data not shown). 
Put together these data indicate considerable 
genetic diversity within the viral strains present 
in the lymphoma. 
 
We performed EBNA3A sequencing in five 
EBV+DLBCL and four EBV+DLBCL-PTLD tissues 
in regions associated with ten functionally iden-
tified CD8+ T-cell epitopes presented by seven 
different (plus one currently unidentified) HLA 
class I alleles. This showed conservation of HLA 
class I epitopes in 85/90 epitopes tested (Table 
4). Exceptions include DL67, a Pacific Islander 
who showed a type 1 EBNA2 by PCR but an HLA 
B*08 epitope (LLRGRAYGQ as opposed to 
FLRGRAYGL) identical to the type 2 prototype 
viral strain AG876. Extensive LMP1 and EB-
NA3A sequencing (data not shown) in this case 
showed the patient to be compatible to a previ-
ously reported viral sub-strain in which both 
type 1 and type 2 features are known to co-
exist, that was originally identified in Papua New 
Guinea [23]. In all nine lymphoma cases the 
same HLA A*29 epitope (VSSDRGVAC as op-
posed to VFSDRGVAC) was identified. 
VSSDRGVAC is the most frequent variant ob-
served in Australian Caucasians [24]. The HLA 
B*35.01 epitope YPLHEQHGMA was present in 
5/9 cases. YPLHKQHGMA was observed in one 
EBV+DLBCL-PTLD case, and YTLHEQHGMA in 
three EBV+DLBCL cases. 
 
No phylogenetic distinction between EBV 
strains present in EBV+DLBCL versus 
EBV+DLBCL-PTLD 
 
Phylogenetic analysis was performed to assess 
for relationships between viral strains present in 
patient biopsy samples. We compared results 
between EBV+DLBCL and EBV+DLBCL-PTLD. 
Previous work has shown that the phylogeny of 
Figure 3. Phylogenetic Analysis of 
EBNA1 and LMP1 protein sequences 
from EBV+DLBCL and EBV+DLBCL-
PTLD. The phylogeny of EBV strains 
can be inferred from EBNA1 and 
LMP1 strain variation analysis, rela-
tive to the prototype type 1 strain B95
-8, the prototype type 2 strain AG876, 
and the type 1 strain GD1. With EB-
NA1 (A), the tree had 4 main 
branches. For LMP1 (B), a five branch 
pylogenetic tree was made. The first 
large cluster in EBNA1 is separated 
into 3 clusters in the LMP1 phylogram 
because of the 30bp deletion in the C
-terminus (not present in B95-8). The 
first (PDL4 and DL26) samples has 
no 30bp deletion, the second (PDL6, 
DL4, DL29 and DL82) has the 30bp 
deletion and the third (AG876, GD1) 
contains the deletion. DL: 
EBV+DLBCL and PDL: EBV+DLBCL-
PTLD.  
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Table 4. EBNA3A HLA class 1 epitope polymorphisms compared to B95-8, GD1 and AG876 strains. 
HLA Class I allele restriction 
Samples A*24 A*29 A*30.02 B*07 B*07 B*08 *B*08 B*35.01 B*62 Unknown 
B95-8       RYSIFFDY VFSDGRVAC AYSSWMYSY RPPIFIRRL VPAPAGPIV QAKWRLQTL FLRGRAYGI YPLHEQHGMA LEKARGSTY HLAAQGMAY 
GD1 RYSIFFDY VSSDGRVAC AYSSWMYSY RPPIFIRRL VPAPAGPIV QAKWRLQTL FLRGRAYGL YPLHEQRGMA LEKARGSTY HLAAQGMAY 
PDL3 RYSIFFDY VSSDGRVAC AYSSWMYSY RPPIFIRRL VPAPAGPIV QAKWRLQTL FLRGRAYGL YPLHEQHGMA LEKARGSTY HLAAQGMAY 
PDL4 RYSIFFDY VSSDGRVAC AYSSWMYSY RPPIFIRRL VPAPAGPIV QAKWRLQTL FLRGRAYGL YPLHEQHGMA LEKARGSTY HLAAQGMAY 
PDL7 RYSIFFDY VSSDGRVAC AYSSWMYSY RPPIFIRRL VPAPAGPIV QAKWRLQTL FLRGRAYGL YPLHEQHGMA LEKARGSTY HLAAQGMAY 
PDL8 RYSIFFDY VSSDGRVAC AYSSWMYSY RPPIFIRRL VPAPAGPIV QAKWRLQTL FLRGRAYGL YPLHKQHGMA LEKARGSTY HLAAQGMAY 
DL26 RYSIFFDY VSSDGRVAC AYSSWMYSY RPPIFIRRL VPAPAGPIV QAKWRLQTL FLRGRAYGL YPLHEQHGMA LEKARGSTY HLAAQGMAY 
DL82 RYSIFFDY VSSDGRVAC AYSSWMYSY RPPIFIRRL VPAPAGPIV QAKWRLQTL FLRGRAYGL YPLHEQHGMA LEKARGSTY HLAAQGMAY 
DL29 RYSIFFDY VSSDGRVAC AYSSWMYSY RPPIFIRRL VPAPAGPIV QAKWRLQTL FLRGRAYGL YTLHEQHGMA LEKARGSTY HLAAQGMAY 
DL44 RYSIFFDY VSSDGRVAC AYSSWMYSY RPPIFIRRL VPAPAGPIV QAKWRLQTL FLRGRAYGL YTLHEQHGMA LEKARGSTY HLAAQGMAY 
DL67 RYSIFFDY VSSDGRVAC AYSSWMYSY RPPIFIRRL VPAPAGPIV QAKWRLQTL **LLRGRAYGQ YTLHEQHGMA LEKARGSTY HLAAQGMAY 
AG876 CYSIFFDY VPKDGRGAC AYSSWMYSY RPPIFLRRL VPALAGPIV QVKWRMTTL LLRGRAYGQ YPLHQQHSMA LAKAPRRTY ***H-------- 
Underlined amino acids are different as compared to B95-8. Gray highlighted epitopes indicate differences among studied samples. There were 5/90 differences 
identified. *FLRGRAYGL is the functionally defined HLA B8 epitope. FLRGRAYGI is observed only in B95-8. **DL67 (a Pacific Islander) showed a type 1 EBNA2 by PCR but 
an HLA class I epitope identical to the type 2 EBV strain AG876. Extensive LMP1 and EBNA3A sequencing showed this case to be compatible to a previously reported viral 
sub-strain originally identified in Papua New Guinea [23] ***Amino acid deletion.  
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EBV viral strains can be inferred from EBNA1 
and LMP1 strain variation analysis, relative to 
three strains that have had full-length sequenc-
ing: B95-8, AG876 and GD1. With EBNA1, the 
tree had two main branches. The first branch 
had EBV+DLBCL-PTLD’s PDL4, PDL5, PDL6 and 
EBV+DLBCL’s DL26, DL29 (Figure 3A). The 
other branch then sub-divided into two, one of 
which contained AG876 and the other contain-
ing B95-8 and (in a sub-branch GD1). The 
EBV+DLBCL-PTLD samples PDL3, PDL7 and 
PDL9 were closely clustered to B95-8. For 
LMP1, a three branch phylogenetic tree was 
made (Figure 3B). One branch contained AG876 
and GD1, another DL4 and DL29, and the last 
the remaining samples and B95-8, which again 
was closely clustered to PDL3, PDL7 and PDL9. 
There was broad overlap with the EBNA1 tree. 
However, there were some differences due to 
the presence or absence of a 30bp deletion 
present in the LMP1 C-terminus (this deletion is 
not present in B95-8 but is present in AG876 
and GD1). This resulted in samples that formed 
the first EBNA1 branch, not clustering together 
in the LMP1 phylogram. PDL4 and DL26 sample 
had no 30bp deletion, whereas PDL6, DL4 and 
DL82, DL29 contained the 30bp deletion. The 
presence of clusters containing both 
EBV+DLBCL and PTLD-DLBCL biopsy samples 
suggests no phylogenetic distinction between 
viral strains implicated in DLBCL arising in the 
immunosuppressed versus the overtly immuno-
competent.  
 
Discussion 
 
EBV+DLBCL has a poor outcome relative to EBV
-negative DLBCL, indicating that new ap-
proaches need to be investigated [7-9]. Results 
from cellular immunotherapy in other EBV-
associated malignancies are sufficiently encour-
aging for this modality to be explored in the set-
ting of EBV+DLBCL [13, 25, 26]. However, be-
fore these strategies are undertaken, there are 
a number of fundamental questions that should 
be addressed. These include EBV+DLBCL’s viral 
latency profile, the polymorphisms present 
within relevant EBV T-cell epitopes, and its anti-
gen presentation capability. 
 
Previous studies suggest that EBV+DLBCL gen-
erally have a viral latency type II pattern, i.e. 
expression is limited to EBNA1, LMP1 and 
LMP2. Only a minority of cases showed the EBV-
latency type III pattern seen in LCL in which a 
broad range of EBV-latent antigens including 
EBNA3A are expressed. The EBV-latency pattern 
is of critical importance for the rational design 
of EBV-specific cellular immunotherapies that 
target relevant tumor associated viral antigens. 
The reason for this is that in the hierarchy of 
EBV-latent antigen specific CD8+ T-cell immu-
nity, the dominant response is against EB-
NA2/3A/3B/3C, whereas EBNA1, LMP1 and 
LMP2 CD8+ T-cells are usually sub-dominant 
[27, 28]. Thus if EBV+DLBCL has a restricted 
viral latency profile it will be a major impedi-
ment for cellular immunotherapy.  
 
Studies of EBV-positive cell-lines have broadly 
identified several forms of virus latency. Al-
though classifying EBV-latency types based on 
cell-line data is useful, data from primary tumor 
biopsies indicate that such categorization is 
overly simplistic. Firstly, real-time RT-PCR indi-
cates that patterns of virus gene expression are 
variable between primary tissues of the same 
histology (inter-patient variability) [17-19]. Sec-
ondly, tissue immunohistochemistry demon-
strates differences in expression between ma-
lignant cells within the same biopsy (intra-
patient variability) [29]. Furthermore, inferences 
regarding viral latency are frequently based on 
the use of antibodies to LMP1 (expressed in 
>90% of EBV+DLBCL) and EBNA2 (expressed in 
25-30% of EBV+DLBCL) [4, 8]. The rationale is 
that EBNA2 acts as a transcriptional regulator of 
EBV nuclear antigens, and hence positivity can 
be regarded as a surrogate marker of EB-
NA3A/3B/3C, and to indicate latency type III [8]. 
Prior work in EBV+DLBCL based on antibodies 
to LMP1 and EBNA2 suggest that EBV+DLBCL 
generally have a viral latency type II pattern, i.e. 
expression is limited to EBNA1, LMP1 and 
LMP2. Only a minority of cases showed the EBV-
latency type III pattern seen in LCL in which a 
broad range of EBV-latent antigens including 
EBNA3A are expressed. However, data from 
primary tissues in other EBV-positive malignan-
cies indicates that patterns of virus gene ex-
pression are more accurately identified by real-
time RT-PCR [17]. However our gene expression 
data shows that the inferences from EBNA2 
protein expression should be re-visited. Instead, 
EBV+DLBCL lymphomas have a variant type III 
pattern with EBNA2 down-regulated but the im-
muno-dominant EBNA3A expressed. The same 
expression profile was present in EBV+DLBCL-
PTLD. To our knowledge our study is the first 
attempt to compare latency profiles in immuno-
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suppressed / non-immunosuppressed EBV-
positive DLBCL by real-time RT-PCR. Our data in 
indicate that the presence or absence of iatro-
genic immunosuppression does not influence 
the EBV-viral latency pattern.  
 
Our data indicates considerable genetic diver-
sity within the viral strains detected between 
lymphoma biopsies. The strains were associ-
ated with known polymorphisms in functionally 
identified EBNA1 and LMP1 CD8+ T-cell epi-
topes. For example the HLA A*02 B95-8 de-
fined 9mer LMP1 epitope (YLLEMLWRL) has 
between one and three amino acid differences 
from Ch1 (YFLEILWRL), Ch2 (YFLEILWRL), NC 
(YFLEILWRL) and Med- (YLLEILWRL) sub-strains, 
that were identified in 83% of biopsies tested. 
The Med- found in 3/12 cases does not appear 
to influence HLA peptide binding or recognition 
by YLLEMLWRL-specific CTL clones [30]. How-
ever Ch1, Ch2 and NC have changes in the an-
choring position within the epitopes that do in-
terfere with MHC-I binding and fail to elicit a CTL 
response in chromium release assays [30]. 
However these strains have no differences with 
another well-defined functionally confirmed HLA 
A*02 restricted epitope (YLQQNWWTL) [30, 31]. 
Outside of BL, EBNA1 sequence analysis in EBV-
positive lymphoma samples is limited. We dem-
onstrate considerable genetic diversity from the 
B95-8 strain, with 79% of biopsies harbouring a 
non-P-ala sub-strain. Previous work has shown 
that this sequence polymorphism greatly influ-
ences T-cell recognition [32]. Of note, sub-typing 
covered the amino acid residue 524 located in 
the EBNA1 epitope described by Bell et al. 2008 
[32]. P-ala codes for Threonine (ACT) at the 524 
position (T-cell epitope YNLRRGTAL) whereas 
sub-types P-thr or V-val contain Isoleucine (ATT) 
(coding for YNLRRGIAL) and the P-ala-v2 sub-
type encodes for Valine (GTT) (resulting in 
YNLRRGVAL). In our study, only 3/7 (DLBCL-
PTLD) and 1/7 (EBV+DLBCL) biopsies had the P
-ala sub-type. Polymorphism at this site has pre-
viously been shown to influence CD8+ T-cell 
recognition of an endogenously processed HLA 
B*08 binding EBNA1 epitope [32]. Polymor-
phism in the EBNA1 amino acid residue 524 
site also influences the frequency of EBNA1-
specific CD8+ T-cells that can be generated in-
vitro in pre-therapy blood from patients PTLD 
[33]. In Australia 24.7% are HLA B*08 and 
46.5% type as HLA A*02 [34]. The high inci-
dence of EBNA1 non-P-ala, LMP1 non-B95.8, 
and HLA B*08, HLA A*02 alleles in our popula-
tion has implications for future vaccines, which 
will need to be designed to cater for EBNA1 and 
LMP1 strain variation in epitope encoding re-
gions. Any future EBV vaccine that exclusively 
delivers the B95-8 sequence is likely to stimu-
late CD8+ T-cells which in a significant propor-
tion of individuals may have a limited capacity 
in recognizing the EBNA1 and LMP1 epitopes 
encoded by the EBV sub-strain within the tumor.  
 
Our data in indicate that the presence or ab-
sence of iatrogenic immunosuppression does 
not influence the EBV-viral latency pattern. To 
further examine the relationship between 
EBV+DLBCL and EBV+DLBCL-PTLD, we typed 
viral strains so as to perform a phylogenetic 
analysis. The lack of phylogenetic distinction 
that we observed between the viral strains iden-
tified in EBV+DLBCL and EBV+DLBCL-PTLD bi-
opsy samples further emphasize the similarities 
in viral biology between the two entities. Further 
work is required to establish the pathogenic 
links between EBV+DBLCL and EBV+DLBCL-
PTLD.  
 
Latency III is the expression profile used during 
infectious mononucleosis [35]. Normally, the 
cytotoxic T-lymphocyte (CTL) response targets 
the immuno-dominant EBNA2,3A,3B,3C latent 
proteins [27]. The CTL response eliminates EBV-
latently infected cells before they develop into a 
pathogenic lymphoproliferation. This is exempli-
fied in individuals who develop PTLD due to 
iatrogenic immunosuppression following organ 
transplantation. Selective immune impairment 
in EBV-positive HL suggests a similar role of 
immunopathogenesis in HL arising in immuno-
competent vs immunodeficient [36, 37]. Recon-
stitution of EBV-specific CTL has been associ-
ated with objective clinical response in EBV-
positive lymphomas arising in both overtly im-
munocompetent and immunosuppressed pa-
tients, and may be a potential strategy for 
EBV+DLBCL [13, 26, 38, 39]. Results to date 
suggest cellular immunotherapy is relatively low-
risk and might be an attractive option for the 
older patient. Antigen processing and presenta-
tion is known to be intact in EBV-positive PTLD 
and in LCL. We observed that HLA class I, TAP1 
and TAP2 in EBV+DLBCL expression were 
equivalent to EBV+DLBCL-PTLD (and EBV-
negative DLBCL), and was greater than a control 
LCL in the majority of cases. In contrast to EB-
NA1 and LMP1, we observed extensive conser-
vation of functionally defined CD8+ T-cell epi-
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topes (85/90 or 94% of epitopes sequenced) 
encoded by the immuno-dominant EBNA3A, 
making this an attractive immunotherapy target. 
All nine patients exhibited the HLA A*29 epitope 
VSSDRGVAC (which is identical to GD1, but dis-
tinct to B95-8’s VFSDRGVAC). This is the most 
frequent form of the epitope seen in Australian 
Caucasians and does not appear to influence 
immunogenicity [24]. The 5/90 epitope varia-
tions included an EBV+DLBCL case in which the 
HLA B*08 epitope LLRGRAYGQ (identical to the 
type 2 prototype viral strain AG876), and an 
EBV+DLBCL-PTLD case where the HLA B*35.01 
epitope YPLHKQHGMA was found. These vari-
ants are known to be essentially unrecognized 
by FLRGRAYGL and YPLHEQHGMA specific CTL 
respectively [40]. There were also three 
EBV+DLBCL cases of YTLHEQHGMA. This epi-
tope shows reduced recognition by YPLHEQH-
GMA specific CTL [41].  
 
EBV+DLBCL have a highly adverse outcome to 
chemotherapy relative to EBV-negative DLBCL 
[7-10]. We demonstrate that EBV+DLBCL has 
many similarities to EBV+DLBCL-PTLD, including 
expression of EBNA3A, indicating that such an 
approach may be feasible in EBV-positive 
DLBCL arising in the overtly immunocompetent 
as well as in the context of PTLD. Further stud-
ies are required to assess the nature of EBV 
specific T-cell immunity in these patients. 
Strategies such as immunotherapies specifically 
targeting the virus within the malignant cell 
should be actively explored.  
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